1,556 followers
Results from @ThePCCTC phase I trial of the antibody drug conjugate ASG-5ME in metastatic castration-resistant #prostatecancer (NCT01228760): https://t.co/XFc3fSSjQp https://t.co/qfEyHZGfPN
Results from @ThePCCTC phase I trial of the antibody drug conjugate ASG-5ME in metastatic castration-resistant #prostatecancer (NCT01228760): https://t.co/XFc3fSSjQp https://t.co/qfEyHZGfPN
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. https://t.co/K8kRKAcqlY https://t.co/uLgt0WRy64